Carmen Bozic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carmen Bozic has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
S. Richman
Biogen Idec Inc. Cambridge MA USA
4 shared publicationsG. Bloomgren
3 shared publicationsM. Subramanyam
Biogen Idec Inc. Cambridge MA USA
3 shared publicationsT. Plavina
Biogen Idec Inc. Cambridge MA USA
3 shared publicationsA. Natarajan
2 shared publicationsA. Sandrock
2 shared publications
Latest Publications
- 30 November 2013
- Published by Wiley in European Journal of Neurology
- Vol. 21 (2) , 299-304
Anti‐JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial
Background and purpose: Progressive multifocal leukoencephalopathy (PML) is caused by reactivation of JC virus (JCV) infection due to combined host and viral factors. Anti‐JCV antibodies provide a means to assess JCV exposure and stratify PML risk. The reported seroprevalence of anti‐JCV antibodies varies from 39% to 91% depending on assay methodology and population studied. A two‐step anti‐JCV antibody assay (STRATIFY JCV™; Focus Diagnostics, Cypress, CA, USA) detected anti‐JCV antibodies in approximately 55% of multiple sclerosis (MS) patients. This study describes the prevalence of anti‐JCV antibodies in a large, multinational MS population.Methods: This cross‐sectional epidemiology study was designed to enroll a minimum of 2000 patients with an MS diagnosis of any type, irrespective of treatment, from Europe, Canada and Australia. Anti‐JCV antibody prevalence was determined by STRATIFY JCV; the effects of demographic and disease characteristics were evaluated.Results: A total of 7724 patients from 10 countries participated in the study. Overall anti‐JCV antibody prevalence was 57.1% (95% confidence interval 56.0%–58.2%). Seroprevalence was significantly associated with increasing age, gender and country of current residence (P < 0.0001). No significant differences in anti‐JCV antibody prevalence were associated with MS disease characteristics, including duration and type of MS and number and duration of MS therapies.Conclusions: Overall seroprevalence of anti‐JCV antibodies in MS patients from Europe, Canada and Australia was consistent with previous studies using the STRATIFY JCV assay. Anti‐JCV prevalence differed significantly by age, gender and country, but no geographical pattern was evident. Disease and treatment type were not associated with differences in anti‐JCV antibody status.
- 30 November 2013
- Published by Wiley in European Journal of Neurology
- Vol. 21 (2) , 299-304
Anti‐JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial
Background and purpose: Progressive multifocal leukoencephalopathy (PML) is caused by reactivation of JC virus (JCV) infection due to combined host and viral factors. Anti‐JCV antibodies provide a means to assess JCV exposure and stratify PML risk. The reported seroprevalence of anti‐JCV antibodies varies from 39% to 91% depending on assay methodology and population studied. A two‐step anti‐JCV antibody assay (STRATIFY JCV™; Focus Diagnostics, Cypress, CA, USA) detected anti‐JCV antibodies in approximately 55% of multiple sclerosis (MS) patients. This study describes the prevalence of anti‐JCV antibodies in a large, multinational MS population.Methods: This cross‐sectional epidemiology study was designed to enroll a minimum of 2000 patients with an MS diagnosis of any type, irrespective of treatment, from Europe, Canada and Australia. Anti‐JCV antibody prevalence was determined by STRATIFY JCV; the effects of demographic and disease characteristics were evaluated.Results: A total of 7724 patients from 10 countries participated in the study. Overall anti‐JCV antibody prevalence was 57.1% (95% confidence interval 56.0%–58.2%). Seroprevalence was significantly associated with increasing age, gender and country of current residence (P < 0.0001). No significant differences in anti‐JCV antibody prevalence were associated with MS disease characteristics, including duration and type of MS and number and duration of MS therapies.Conclusions: Overall seroprevalence of anti‐JCV antibodies in MS patients from Europe, Canada and Australia was consistent with previous studies using the STRATIFY JCV assay. Anti‐JCV prevalence differed significantly by age, gender and country, but no geographical pattern was evident. Disease and treatment type were not associated with differences in anti‐JCV antibody status.
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , S41.002
Anti-JCV Antibody Prevalence in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Natalizumab: Baseline Results of STRATIFY-2 (S41.002)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , S41.002
Anti-JCV Antibody Prevalence in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Natalizumab: Baseline Results of STRATIFY-2 (S41.002)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , S41.001
Updated Incidence of Progressive Multifocal Leukoencephalopathy in Natalizumab-Treated Multiple Sclerosis Patients Stratified by Established Risk Factors (S41.001)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , S41.001
Updated Incidence of Progressive Multifocal Leukoencephalopathy in Natalizumab-Treated Multiple Sclerosis Patients Stratified by Established Risk Factors (S41.001)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , P07.058
Classification of Natalizumab Cases with Progressive Multifocal Leukoencephalopathy (P07.058)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , P07.058
Classification of Natalizumab Cases with Progressive Multifocal Leukoencephalopathy (P07.058)
- 17 August 2011
- Published by Wiley in Annals of Neurology
- Vol. 70 (5) , 742-750
Anti‐John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY‐1
Objective: A study was undertaken to define the prevalence of anti‐JC virus (JCV) antibodies in multiple sclerosis (MS) patients and to evaluate the analytical false‐negative rate of a 2‐step anti‐JC virus antibody assay.Methods: STRATIFY‐1 is an ongoing, longitudinal, observational study of relapsing MS patients in the United States who are being treated or considering treatment with natalizumab. Baseline serum and plasma samples were collected for anti‐JC virus antibody detection using an analytically validated, 2‐step, virus‐like particle‐based enzyme‐linked immunosorbent assay. Urine was collected for JC virus DNA detection.Results: At baseline (n = 1,096), overall anti‐JC virus antibody prevalence was 56.0% (95% confidence interval [CI], 53.0‐59.0) in STRATIFY‐1 patients, with an assay false‐negative rate of 2.7% (95% CI, 0.9–6.2). Prevalence was significantly lower in females (53.4%; 95% CI, 49.9–56.8) than males (64.3%; 95% CI, 58.2–70.0) and increased with age, p = 0.0019 and p = 0.0001, respectively. Prevalence was similar in patients regardless of natalizumab exposure or prior immunosuppressant use, p = 0.9709 and p = 0.6632, respectively. STRATIFY‐1 results were generally consistent with those observed in another large North American cohort, TYGRIS‐US (n = 1,480).Interpretation: Baseline results from STRATIFY‐1 are consistent with other studies utilizing this assay that demonstrate a 50 to 60% prevalence of anti‐JC virus antibodies, a low false‐negative rate, and an association of increasing age and male gender with increasing anti‐JC virus antibody prevalence. Neither natalizumab exposure nor prior immunosuppressant use appear to affect prevalence. Longitudinal data from STRATIFY‐1 will confirm the stability of anti‐JC virus antibody prevalence over time. ANN NEUROL 2011
- 17 August 2011
- Published by Wiley in Annals of Neurology
- Vol. 70 (5) , 742-750
Anti‐John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY‐1
Objective: A study was undertaken to define the prevalence of anti‐JC virus (JCV) antibodies in multiple sclerosis (MS) patients and to evaluate the analytical false‐negative rate of a 2‐step anti‐JC virus antibody assay.Methods: STRATIFY‐1 is an ongoing, longitudinal, observational study of relapsing MS patients in the United States who are being treated or considering treatment with natalizumab. Baseline serum and plasma samples were collected for anti‐JC virus antibody detection using an analytically validated, 2‐step, virus‐like particle‐based enzyme‐linked immunosorbent assay. Urine was collected for JC virus DNA detection.Results: At baseline (n = 1,096), overall anti‐JC virus antibody prevalence was 56.0% (95% confidence interval [CI], 53.0‐59.0) in STRATIFY‐1 patients, with an assay false‐negative rate of 2.7% (95% CI, 0.9–6.2). Prevalence was significantly lower in females (53.4%; 95% CI, 49.9–56.8) than males (64.3%; 95% CI, 58.2–70.0) and increased with age, p = 0.0019 and p = 0.0001, respectively. Prevalence was similar in patients regardless of natalizumab exposure or prior immunosuppressant use, p = 0.9709 and p = 0.6632, respectively. STRATIFY‐1 results were generally consistent with those observed in another large North American cohort, TYGRIS‐US (n = 1,480).Interpretation: Baseline results from STRATIFY‐1 are consistent with other studies utilizing this assay that demonstrate a 50 to 60% prevalence of anti‐JC virus antibodies, a low false‐negative rate, and an association of increasing age and male gender with increasing anti‐JC virus antibody prevalence. Neither natalizumab exposure nor prior immunosuppressant use appear to affect prevalence. Longitudinal data from STRATIFY‐1 will confirm the stability of anti‐JC virus antibody prevalence over time. ANN NEUROL 2011